Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist

被引：0
|
作者：
Abraham, W
Koren, M
Bichet, DG
Verbalis, JG
Klapholz, M
Selaru, P
Bakker-Arkema, RG
Rummel, SA
机构：
[1] Univ Cincinnati, Coll Med, Dept Cardiol, Cincinnati, OH USA
[2] Jacksonville Ctr Clin Res, Jacksonville, FL USA
[3] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada
[4] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[5] Univ Med & Dent New Jersey, Newark, NJ 07103 USA
[6] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Ann Arbor, MI USA
来源：
EUROPEAN HEART JOURNAL | 2000年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1848
引用
收藏
页码：345 / 345
页数：1
相关论文
共 50 条
  • [41] BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats
    Kazama, I
    Hatano, R
    Michimata, M
    Suzuki, K
    Arata, T
    Suzuki, M
    Miyama, N
    Sato, A
    Satomi, S
    Ejima, Y
    Sasaki, S
    Matsubara, M
    KIDNEY INTERNATIONAL, 2005, 67 (05) : 1855 - 1867
  • [42] Vasopressin V1a and V2 receptor mRNA in deoxycorticosterone acetate salt hypertension in the rat
    Risvanis, J
    Johnston, CI
    Phillips, PA
    Burrell, LM
    CLINICAL SCIENCE, 1998, 94 (05) : 517 - 523
  • [43] The magnocellular vasopressin neurones of the rat hypothalamus express V1a and V1b but not V2 vasopressin receptor mRNAs
    Hurbin, A
    Boissin-Agasse, L
    Orcel, H
    Rabié, A
    Joux, N
    Desarménien, MG
    Richard, P
    Moos, FC
    JOURNAL OF PHYSIOLOGY-LONDON, 1998, 509P : 87P - 87P
  • [44] Structurally novel V2-selective and dual V1A/V2 vasopressin receptor antagonists.
    Dyatkin, AB
    Maryanoff, BE
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    DeGaravilla, L
    Demarest, K
    Gunnet, J
    Look, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A93 - A93
  • [45] Bridged bicyclic vasopressin receptor antagonists V2-selective or dual V1a/V2 activity
    Dyatkin, AB
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Gunnet, JW
    Hagemann, W
    Look, R
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) : 3081 - 3084
  • [46] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Shin Nakayama
    Mahmood Amiry-Moghaddam
    Ole Petter Ottersen
    Anish Bhardwaj
    Neurocritical Care, 2016, 24 : 273 - 282
  • [47] Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans
    Shimizu, K
    CLINICAL NEPHROLOGY, 2003, 59 (03) : 164 - 173
  • [48] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Nakayama, Shin
    Amiry-Moghaddam, Mahmood
    Ottersen, Ole Petter
    Bhardwaj, Anish
    NEUROCRITICAL CARE, 2016, 24 (02) : 273 - 282
  • [49] Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
    Mondritzki, T. Thomas
    Boehme, P.
    Sandner, P.
    Dinh, W.
    Hueser, J.
    Truebel, H.
    Kolkhof, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 335 - 335
  • [50] Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
    Tahara, A
    Tsukada, J
    Tomura, Y
    Kusayama, T
    Wada, KI
    Ishii, N
    Taniguchi, N
    Suzuki, T
    Yatsu, T
    Uchida, W
    Shibasaki, M
    PHARMACOLOGICAL RESEARCH, 2005, 51 (03) : 275 - 281
12345